Onconetix Research Development from 2010 to 2026

ONCO Stock  USD 0.77  0.29  27.36%   
Onconetix Research Development yearly trend continues to be very stable with very little volatility. Research Development is likely to drop to about 168.6 K. During the period from 2010 to 2026, Onconetix Research Development quarterly data regression pattern had sample variance of 1.1 T and median of  60,174. View All Fundamentals
 
Research Development  
First Reported
2010-12-31
Previous Quarter
177.5 K
Current Value
168.6 K
Quarterly Volatility
1.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Onconetix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Onconetix's main balance sheet or income statement drivers, such as Interest Income of 15.39, Depreciation And Amortization of 883.1 K or Gross Profit of 1.3 M, as well as many indicators such as Price To Sales Ratio of 0.75, Dividend Yield of 0.096 or PTB Ratio of 0.2. Onconetix financial statements analysis is a perfect complement when working with Onconetix Valuation or Volatility modules.
  
Build AI portfolio with Onconetix Stock
Check out the analysis of Onconetix Correlation against competitors.
To learn how to invest in Onconetix Stock, please use our How to Invest in Onconetix guide.
Evaluating Onconetix's Research Development across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Onconetix's fundamental strength.

Latest Onconetix's Research Development Growth Pattern

Below is the plot of the Research Development of Onconetix over the last few years. It is Onconetix's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Onconetix's overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

Onconetix Research Development Regression Statistics

Arithmetic Mean531,252
Geometric Mean154,398
Coefficient Of Variation200.80
Mean Deviation683,573
Median60,174
Standard Deviation1,066,766
Sample Variance1.1T
Range4.1M
R-Value0.38
Mean Square Error1T
R-Squared0.14
Significance0.13
Slope80,153
Total Sum of Squares18.2T

Onconetix Research Development History

2026168.6 K
2025177.5 K
2024154.4 K
20231.9 M
20224.1 M
20211.3 M
2020524.9 K

About Onconetix Financial Statements

Onconetix investors utilize fundamental indicators, such as Research Development, to predict how Onconetix Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Research Development177.5 K168.6 K

Pair Trading with Onconetix

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Onconetix position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Onconetix will appreciate offsetting losses from the drop in the long position's value.

Moving together with Onconetix Stock

  0.66OSE OSE Pharma SAPairCorr

Moving against Onconetix Stock

  0.83EQ EquilliumPairCorr
  0.8DRTS Alpha Tau MedicalPairCorr
  0.65GXEA Galapagos NVPairCorr
  0.626C1 CytomX TherapeuticsPairCorr
  0.57VERA Vera Therapeutics Sell-off TrendPairCorr
The ability to find closely correlated positions to Onconetix could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Onconetix when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Onconetix - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Onconetix to buy it.
The correlation of Onconetix is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Onconetix moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Onconetix moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Onconetix can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Onconetix offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Onconetix's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Onconetix Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Onconetix Stock:
Check out the analysis of Onconetix Correlation against competitors.
To learn how to invest in Onconetix Stock, please use our How to Invest in Onconetix guide.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Will Biotechnology sector continue expanding? Could Onconetix diversify its offerings? Factors like these will boost the valuation of Onconetix. Anticipated expansion of Onconetix directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Onconetix data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
1.2 K
Revenue Per Share
2.144
Quarterly Revenue Growth
(0.25)
Return On Assets
(0.07)
Return On Equity
(2.21)
Understanding Onconetix requires distinguishing between market price and book value, where the latter reflects Onconetix's accounting equity. The concept of intrinsic value - what Onconetix's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Onconetix's price substantially above or below its fundamental value.
It's important to distinguish between Onconetix's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Onconetix should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Onconetix's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.